Value through Innovation02 September 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

09.07.2012

Boehringer Ingelheim Establishes Translational Research Collaboration with Harvard University in Areas of Unmet Medical Need

05.07.2012

Boehringer Ingelheim announces changes to Board of Managing Directors: Joachim Hasenmaier to lead new Board Division Consumer Healthcare and Animal Health

28.06.2012

New publication in The Lancet: Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride

- EX US & UK Medical Media Only
25.06.2012

No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa® (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery

20.06.2012

First study to evaluate alternative to warfarin for mechanical heart valve patients launched with Pradaxa® (dabigatran etexilate)

- For Non-US, Non-UK & Non-Canadian Media Only
18.06.2012

AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin

- For Non-US, Non-UK & Non-Canadian Media Only
18.06.2012

Boehringer Ingelheim BioXcellence:
Distinctive brand for the biopharmaceutical contract manufacturing business

12.06.2012

Boehringer Ingelheim once again certified as a family-friendly company

11.06.2012

Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine

- EX UK. Medical Media Only.
09.06.2012

New analysis presented at ADA shows improvement in albuminuria with linagliptin in patients at high risk of declining renal function

- EX US & UK. Medical Media Only.
09.06.2012

New data demonstrate sustained glucose reduction and weight loss up to 90 weeks with investigational SGLT-2 inhibitor, empagliflozin*

- EX US & UK. Medical Media Only.
09.06.2012

New linagliptin phase III data demonstrate significant reductions in blood glucose with no additional risk of hypoglycaemia when combined with insulin in patients with type 2 diabetes

- EX US & UK. Medical Media Only.
06.06.2012

FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes

- For Non-US, Non-UK & Non-Canadian Media Only
05.06.2012

Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes at the 72nd American Diabetes Association Scientific Sessions

- EX US & UK. Medical Media Only.
04.06.2012

Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial

- For NON-US media only
01.06.2012

Boehringer Ingelheim launches first-of-a-kind fundraising model to support disease awareness projects

- For NON-US Media Only
31.05.2012

Boehringer Ingelheim expands development capacities with new technical centre

30.05.2012

Boehringer Ingelheim further strengthens animal health presence in China: Manufacturing joint venture for veterinary vaccines